TN2011000437A1 - Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof - Google Patents

Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Info

Publication number
TN2011000437A1
TN2011000437A1 TN2011000437A TN2011000437A TN2011000437A1 TN 2011000437 A1 TN2011000437 A1 TN 2011000437A1 TN 2011000437 A TN2011000437 A TN 2011000437A TN 2011000437 A TN2011000437 A TN 2011000437A TN 2011000437 A1 TN2011000437 A1 TN 2011000437A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical compositions
methods
receptor
human glp
substituted azoanthracene
Prior art date
Application number
TN2011000437A
Other languages
English (en)
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of TN2011000437A1 publication Critical patent/TN2011000437A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
TN2011000437A 2009-03-30 2011-08-25 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof TN2011000437A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (fr) 2009-03-30 2010-03-30 Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
TN2011000437A1 true TN2011000437A1 (en) 2013-03-27

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000437A TN2011000437A1 (en) 2009-03-30 2011-08-25 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Country Status (18)

Country Link
US (3) US8383644B2 (fr)
EP (1) EP2413693B1 (fr)
JP (1) JP5755217B2 (fr)
KR (1) KR101732978B1 (fr)
CN (1) CN102378574B (fr)
AU (1) AU2010232750B2 (fr)
BR (1) BRPI1013579A2 (fr)
CA (1) CA2757084C (fr)
DK (1) DK2413693T3 (fr)
EA (1) EA023430B1 (fr)
ES (1) ES2553645T3 (fr)
HK (1) HK1164050A1 (fr)
IL (1) IL214822A (fr)
MA (1) MA33219B1 (fr)
MX (1) MX2011010347A (fr)
SG (1) SG174205A1 (fr)
TN (1) TN2011000437A1 (fr)
WO (1) WO2010114824A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102378574B (zh) 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
CA2850987C (fr) 2011-10-17 2019-10-15 Biotheryx, Inc. Amides a biaryle alkyle substitue
MX366685B (es) * 2013-01-17 2019-07-19 Vtv Therapeutics Llc Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
WO2016033105A1 (fr) 2014-08-29 2016-03-03 The Board Of Regents Of The University Of Texas System Nouveaux analogues de la capsazépine pour le traitement du cancer et d'autres maladies prolifératives
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
KR20210005843A (ko) 2018-05-08 2021-01-15 브이티브이 테라퓨틱스 엘엘씨 Glp1r 작용제의 치료적 용도
TWI707683B (zh) * 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
JP2023528726A (ja) * 2020-04-01 2023-07-06 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法
JP2023528565A (ja) * 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202210462A (zh) 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 （ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基丙酸甲酯及其鹽的製備方法
WO2021242807A1 (fr) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Procédés de préparation de méthyl(s)-2-amino-3-(4-(2,3-diméthylpyridin-4-yl)phényl)propionate et de sels d'acide chlorhydrique associés
US20230348412A1 (en) * 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist
CN115667219A (zh) * 2020-05-28 2023-01-31 杭州中美华东制药有限公司 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
TW202210487A (zh) 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種ｇｌｐ－１受體激動劑游離鹼的製備方法
WO2021242806A1 (fr) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Intermédiaires et procédés de préparation d'un agoniste du récepteur glp-1
US20230322756A1 (en) 2020-09-01 2023-10-12 Jiangsu Hengrui Medicine Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
US20230382921A1 (en) * 2020-09-21 2023-11-30 Vtv Therapeutics Llc Amorphous Form of Isoquinoline Derivative
WO2022076503A1 (fr) * 2020-10-08 2022-04-14 Eli Lilly And Company Composés de 6-méthoxy-3,4-dihydro-1h-isoquinoline utiles dans le traitement du diabète
WO2022078152A1 (fr) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation
CN115461334A (zh) 2020-11-27 2022-12-09 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
EP4317142A1 (fr) 2021-03-22 2024-02-07 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Agoniste du récepteur de glp-1 de type thiophène et son utilisation
WO2022202864A1 (fr) 2021-03-24 2022-09-29 塩野義製薬株式会社 Composition pharmaceutique contenant un agoniste du récepteur glp-1 comportant un cycle fusionné
WO2022262615A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Composé anthracène, son procédé de préparation et son utilisation médicale
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
IL309235A (en) 2021-06-24 2024-02-01 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd GLP-1 receptor agonist and its preparation and use
WO2023029979A1 (fr) * 2021-09-03 2023-03-09 杭州中美华东制药有限公司 Procédé de préparation d'un intermédiaire agoniste du récepteur de glp-1
WO2023038039A1 (fr) 2021-09-08 2023-03-16 塩野義製薬株式会社 Médicament destiné à la prévention et au traitement de maladies liées à l'activité anti-obésité
CA3233453A1 (fr) 2021-09-28 2023-04-06 Meimei Chen Composition solide d'agoniste du recepteur glp-1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (fr) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. Dérivés de 1,4-benzoxazine, leur préparation et leur application
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
EP1147094A1 (fr) * 1999-01-15 2001-10-24 Novo Nordisk A/S Agonistes non peptidiques de glp-1
CA2441790A1 (fr) 2001-03-27 2002-10-03 Actelion Pharmaceuticals Ltd. Derives de 1,2,3,4-tetrahydro-isoquinoline en tant qu'antagonistes du recepteur de l'urotensine ii
ATE348828T1 (de) 2001-10-19 2007-01-15 Transtech Pharma Inc Beta-carbolin-derivate als ptp-inhibitoren
BR0215212A (pt) * 2001-12-21 2004-12-07 Novo Nordisk As Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
JP4637089B2 (ja) * 2003-03-26 2011-02-23 アクテリオン ファーマシューティカルズ リミテッド アセトアミド誘導体
WO2005014534A1 (fr) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Composes aryle et heteroaryle, compositions, et methodes d'utilisation
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2008118935A1 (fr) * 2007-03-26 2008-10-02 Neurogen Corporation Composés et procédés de préparation d'aminométhyl-2,3,8,9-tétrahydro-7h-1,4-dioxino[2,3-e]indol-8-ones substitués
MX2010009752A (es) 2008-03-07 2010-09-30 Transtech Pharma Inc Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
WO2009126709A1 (fr) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands pour le récepteur de glp-1 et procédés de découverte de ceux-ci
CN102378574B (zh) 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
US8501982B2 (en) 2010-06-09 2013-08-06 Receptos, Inc. GLP-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
AU2010232750B2 (en) 2015-10-29
US20130096150A1 (en) 2013-04-18
JP2012522060A (ja) 2012-09-20
ES2553645T3 (es) 2015-12-10
IL214822A0 (en) 2011-11-30
CN102378574B (zh) 2013-11-20
CA2757084C (fr) 2017-08-29
CN102378574A (zh) 2012-03-14
WO2010114824A1 (fr) 2010-10-07
US20150148539A1 (en) 2015-05-28
EP2413693B1 (fr) 2015-09-09
JP5755217B2 (ja) 2015-07-29
EP2413693A1 (fr) 2012-02-08
US8987295B2 (en) 2015-03-24
KR20120006506A (ko) 2012-01-18
MA33219B1 (fr) 2012-04-02
HK1164050A1 (en) 2012-09-21
US8383644B2 (en) 2013-02-26
EA201171197A1 (ru) 2012-04-30
SG174205A1 (en) 2011-10-28
IL214822A (en) 2016-08-31
US9175003B2 (en) 2015-11-03
AU2010232750A1 (en) 2011-09-08
DK2413693T3 (en) 2015-11-16
BRPI1013579A2 (pt) 2020-11-03
WO2010114824A8 (fr) 2011-10-06
EA023430B1 (ru) 2016-06-30
CA2757084A1 (fr) 2010-10-07
EP2413693A4 (fr) 2012-08-22
EA201171197A8 (ru) 2014-10-30
MX2011010347A (es) 2011-11-29
KR101732978B1 (ko) 2017-05-08
US20110160198A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
WO2015157559A3 (fr) Saxitoxines 10',11'-modifiées pour le traitement de la douleur
BR112012018386A2 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
EP2037739A4 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
IN2014DN08582A (fr)
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
IL206738A0 (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same